Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamic and pleiotropic effects of rivaroxaban in coronary artery disease and atrial fibrillation
2020-005110-17Phase 4Terminated
- Sponsor
- Azienda Ospedaliero-Universitaria Maggiore della Carità
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of rivaroxaban and aspirin in coronary arteriosclerosis and Atrial fibrillation (AFib) (3 arms), sponsored by Azienda Ospedaliero-Universitaria Maggiore della Carità. Primary endpoints: Change in anti-Xa activity over time, Platelet aggregation and 3 more. Started Jun 2021; status: terminated.
02
Drugs
rivaroxabanaspirin
03
Conditions
coronary arteriosclerosisAtrial fibrillation (AFib)
Beyond the preview
Go deeper on 2020-005110-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005110-17.